€4.68
1.27% yesterday
Xetra, Jun 30, 05:36 pm CET
ISIN
DE000A11QVV0
Symbol
HPHA
Index
Sector
Industry

Heidelberg Pharma Stock price

€4.68
+1.30 38.46% 1M
+2.24 91.80% 6M
+2.24 91.80% YTD
+2.08 80.00% 1Y
+0.04 0.86% 3Y
+0.46 10.90% 5Y
+1.04 28.54% 10Y
-9.02 65.84% 20Y
Xetra, Closing price Mon, Jun 30 2025
-0.06 1.27%
ISIN
DE000A11QVV0
Symbol
HPHA
Index
Sector
Industry

Key metrics

Basic
Market capitalization
€193.4m
Enterprise Value
€172.9m
Net debt
positive
Cash
€20.7m
Shares outstanding
46.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
28.23 | 20.95
EV/Sales
25.24 | 18.73
EV/FCF
negative
P/B
8.81
Financial Health
Equity Ratio
50.83%
Return on Equity
-62.79%
ROCE
-46.72%
ROIC
-82.55%
Debt/Equity
0.01
Financials (TTM | estimate)
Revenue
€6.9m | €9.2m
EBITDA
€-21.2m | €-33.7m
EBIT
€-22.1m
Net Income
€-20.8m | €-33.5m
Free Cash Flow
€-28.0m
Growth (TTM | estimate)
Revenue
-24.31% | 34.76%
EBITDA
-14.59% | -46.48%
EBIT
-13.98%
Net Income
-13.95% | -72.96%
Free Cash Flow
18.57%
Margin (TTM | estimate)
Gross
73.80%
EBITDA
-309.35% | -364.64%
EBIT
-322.15%
Net
-303.90% | -363.09%
Free Cash Flow
-408.29%
More
EPS
€-0.45
FCF per Share
€-0.60
Short interest
-
Employees
105.00
Rev per Employee
€70.00k
Show more

Is Heidelberg Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Heidelberg Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Heidelberg Pharma forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Heidelberg Pharma forecast:

Buy
88%
Hold
13%

Financial data from Heidelberg Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Feb '25
+/-
%
6.85 6.85
24% 24%
100%
- Direct Costs 1.80 1.80
2% 2%
26%
5.06 5.06
30% 30%
74%
- Selling and Administrative Expenses 7.11 7.11
31% 31%
104%
- Research and Development Expense 23 23
15% 15%
341%
-21 -21
15% 15%
-309%
- Depreciation and Amortization 0.88 0.88
1% 1%
13%
EBIT (Operating Income) EBIT -22 -22
14% 14%
-322%
Net Profit -21 -21
14% 14%
-304%

In millions EUR.

Don't miss a Thing! We will send you all news about Heidelberg Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Heidelberg Pharma AG is a holding company, which engages in the development of diagnostic and therapeutic oncology products for the detection and targeted treatment of various types of cancer. It operates through the following segments: Customer Specific Research, Diagnostics, and Therapeutics. The company was founded by Olaf G. Wilhelm, Manfred Schmitt, Viktor Magdolen, Heinrich Graeff, Bernd Gänsbacher, Horst Kessler, Peter Nawroth, and Thomas Luther in September 1997 and is headquartered in Ladenburg, Germany.

Head office Germany
CEO Andreas Pahl
Employees 105
Founded 1997
Website www.heidelberg-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today